Ubs Asset Management Americas Inc Pacira Bio Sciences, Inc. Transaction History

Ubs Asset Management Americas Inc

$417 Billion
Q4 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 104,855 shares of PCRX stock, worth $2.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

104,855

Previous 83,074 26.22%

Holding current value

$2.66 Million

Previous $1.25 Million 57.87%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$15.3 - $20.33 $333,249 - $442,807	21,781 Added 26.22%	104,855 $1.98 Million
Q3 2024 Nov 14, 2024	SELL	$11.7 - $28.46 $267,216 - $649,997	-22,839 Reduced 21.56%	83,074 $1.25 Million
Q2 2024 Aug 13, 2024	BUY	$25.5 - $31.51 $1.42 Million - $1.76 Million	55,777 Added 111.25%	105,913 $3.03 Million
Q3 2023 Nov 13, 2023	BUY	$30.68 - $40.09 $71,361 - $93,249	2,326 Added 4.87%	50,136 $1.54 Million
Q1 2023 May 15, 2023	BUY	$35.53 - $43.38 $164,077 - $200,328	4,618 Added 10.69%	47,810 $1.95 Million
Q3 2022 Nov 14, 2022	SELL	$51.24 - $58.89 $550,061 - $632,184	-10,735 Reduced 19.91%	43,192 $2.3 Million
Q2 2022 Aug 12, 2022	BUY	$51.49 - $81.64 $27,032 - $42,861	525 Added 0.98%	53,927 $3.14 Million
Q1 2022 May 16, 2022	BUY	$60.03 - $76.49 $150,735 - $192,066	2,511 Added 4.93%	53,402 $4.08 Million
Q2 2021 Aug 16, 2021	BUY	$59.18 - $69.99 $217,782 - $257,563	3,680 Added 7.79%	50,891 $3.09 Million
Q1 2021 May 14, 2021	SELL	$59.31 - $78.82 $24,969 - $33,183	-421 Reduced 0.88%	47,211 $3.31 Million
Q4 2020 Mar 01, 2021	BUY	$50.47 - $66.26 $172,859 - $226,940	3,425 Added 7.75%	47,632 $2.85 Million
Q3 2020 Nov 13, 2020	BUY	$51.97 - $63.0 $133,458 - $161,784	2,568 Added 6.17%	44,207 $2.66 Million
Q2 2020 Aug 14, 2020	SELL	$30.8 - $52.47 $185,970 - $316,813	-6,038 Reduced 12.66%	41,639 $2.18 Million
Q1 2020 May 15, 2020	SELL	$28.4 - $50.7 $5,594 - $9,987	-197 Reduced 0.41%	47,677 $1.6 Million
Q4 2019 Feb 14, 2020	BUY	$36.31 - $46.83 $8,750 - $11,286	241 Added 0.51%	47,874 $2.17 Million
Q3 2019 Nov 14, 2019	BUY	$35.66 - $44.99 $145,778 - $183,919	4,088 Added 9.39%	47,633 $1.81 Million
Q2 2019 Aug 15, 2019	BUY	$36.57 - $47.97 $276,542 - $362,749	7,562 Added 21.02%	43,545 $0
Q1 2019 May 14, 2019	BUY	$36.47 - $42.17 $59,920 - $69,285	1,643 Added 4.78%	35,983 $0
Q4 2018 Feb 13, 2019	BUY	$41.31 - $52.16 $205,847 - $259,913	4,983 Added 16.97%	34,340 $1.48 Million
Q2 2018 Aug 14, 2018	BUY	$27.5 - $39.8 $94,215 - $136,354	3,426 Added 13.21%	29,357 $0
Q1 2018 May 14, 2018	BUY	$29.98 - $46.35 $210,789 - $325,886	7,031 Added 37.2%	25,931 $0
Q4 2017 Feb 09, 2018	SELL	$31.85 - $46.95 $177,213 - $261,229	-5,564 Reduced 22.74%	18,900 $0
Q3 2017 Nov 13, 2017	BUY	$35.7 - $39.5 $873,364 - $966,328	24,464	24,464 $0

Others Institutions Holding PCRX

# of Institutions

260

Shares Held

49.8M

Call Options Held

1.03M

Put Options Held

139K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $1.16B
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Pacira Bio Sciences, Inc. Transaction History